cancers

MDPI

Correction

Correction: Nelson et al. *UGT1A1* Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. *Cancers* 2021, *13*, 1566

Ryan S. Nelson [1,2], Nathan D. Seligson [3,4], Sal Bottiglieri [5], Estrella Carballido [6,7], Alex Del Cueto [2], Iman Imanirad [6,7], Richard Levine [6,8], Alexander S. Parker [9], Sandra M. Swain [10], Emma M. Tillman [11] and J. Kevin Hicks [2,6,*]

1 Department of Consultative Services, ARUP Laboratories, Salt Lake City, UT 84108, USA; ryan.nelson@aruplab.com
2 Department of Individualized Cancer Management, Moffitt Cancer Center, Tampa, FL 33612, USA; alex.delcueto@moffitt.org
3 Department of Pharmacotherapy and Translational Research, The University of Florida, Jacksonville, FL 32610, USA; nseligson@cop.ufl.edu
4 Department of Hematology and Oncology, Nemours Children's Specialty Care, Jacksonville, FL 32207, USA
5 Department of Pharmacy, Moffitt Cancer Center, Tampa, FL 33612, USA; salvatore.bottiglieri@moffitt.org
6 Department of Oncological Sciences, University of South Florida, Tampa, FL 33612, USA; estrella.carballido@moffitt.org (E.C.); iman.imanirad@moffitt.org (I.I.); richard.levine@moffitt.org (R.L.)
7 Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA
8 Department of Satellite and Community Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA
9 College of Medicine, University of Florida, Jacksonville, FL 32209, USA; alexander.parker@jax.ufl.edu
10 Georgetown University Medical Center, MedStar Health, Washington, DC 20007, USA; sandra.swain@georgetown.edu
11 Indiana University School of Medicine, Indianapolis, IN 46202, USA; emtillma@iu.edu
* Correspondence: james.hicks@moffitt.org; Tel.: +1-(813)-745-4668

check for updates

Citation: Nelson, R.S.; Seligson, N.D.; Bottiglieri, S.; Carballido, E.; Cueto, A.D.; Imanirad, I.; Levine, R.; Parker, A.S.; Swain, S.M.; Tillman, E.M.; et al. Correction: Nelson et al. *UGT1A1* Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. *Cancers* 2021, *13*, 1566. *Cancers* **2024**, *16*, 3595. https://doi.org/10.3390/cancers16213595

Received: 1 October 2024
Accepted: 9 October 2024
Published: 25 October 2024

Error in Table

In the original publication [1], there was a mistake in Table 1 as published. In certain instances, *UGT1A1* allele frequencies were inadvertently used to describe phenotype frequencies. The corrected Table 1 appears below. The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Table 1. Example *UGT1A1* alleles, predicted phenotype function, and frequencies among racial/ethic groups.

Example *UGT1A1* Alleles and Predicted Function		
Star Nomenclature	**Variant Type**	**Allele Function [α]**
*UGT1A1*36*	$(TA)_5$	Increased Function
*UGT1A1*1*	$(TA)_6$	Normal Function
*UGT1A1*6*	(211G > A)	Decreased Function
*UGT1A1*28*	$(TA)_7$	Decreased Function
*UGT1A1*37*	$(TA)_8$	Decreased Function
Predicted UGT1A1 Phenotypes Based on Commonly Observed Diplotypes		
Predicted UGT1A1 Phenotype	**Frequently Reported Diplotypes [Less Commonly Investigated Diplotypes] [β]**	
Normal Metabolizer (NM)	**1/*1* *[*1/*36, *36/*36]*	
Intermediate Metabolizer (IM)	**1/*28, *1/*6* *[*1/*37, *6/*36, *28/*36, *36/*37]*	

Table 1. *Cont.*

Poor Metabolizer (PM)			*6/*6, *6/*28, *28/*28 [*6/*37, *28/*37, *37/*37]			
***UGT1A1* Allele Frequencies Among Race/Ethnic Groups μ**						
***UGT1A1* Allele**	**African American/ Afro-Caribbean**	**Central/ South Asian**	**East Asian**	**European**	**Latino**	**Sub-Saharan African**
**1*	3%	54%	71%	36%	21%	49%
**6*	<1%	4%	15%	<1%	1%	0%
**28*	37%	41%	15%	32%	40%	40%
**36*	8%	0%	0%	0%	0%	7%
**37*	6%	0%	0%	<1%	0%	4%

α: *UGT1A1* allele function per CPIC and prior investigations [6,11]. **β:** While allelic diversity continues to be recognized, reference laboratories may only test for certain polymorphisms such as **1*, **6*, and **28*. **μ:** Table recreated from CPIC *UGT1A1* Frequency Table [6,12].

Reference

1. Nelson, R.S.; Seligson, N.D.; Bottiglieri, S.; Carballido, E.; Cueto, A.D.; Imanirad, I.; Levine, R.; Parker, A.S.; Swain, S.M.; Tillman, E.M.; et al. *UGT1A1* Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. *Cancers* **2021**, *13*, 1566. [CrossRef] [PubMed]